MAPT and Alzheimer disease: Specifically, the IPE1 fractions exhibited reduced immunoreactivity to the recombinant monoclonal anti‐tau antibody, similar immunoreactivity to the T22 antibody, and increased reactivity to the TOMA2 antibody in NDAN, compared to the reactivity observed in BDTOs from AD.